Related Experiment Videos
Trastuzumab-associated cardiotoxicity.
1Cardiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. dkclinpharm@aol.com
Cancer
|September 19, 2002
Summary
Trastuzumab, a HER2-targeted therapy, can cause cardiotoxicity in breast cancer patients, but severe outcomes are rare. Most cardiac effects are manageable, and patients often improve with treatment or drug discontinuation.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Trastuzumab is a monoclonal antibody for HER2-positive metastatic breast carcinoma.
- Cardiotoxicity is a known risk associated with Trastuzumab therapy, particularly when combined with anthracyclines.
Purpose of the Study:
- To review the incidence, presentation, and management of Trastuzumab-associated cardiotoxicity.
- To compare Trastuzumab-induced cardiac effects with anthracycline-induced cardiomyopathy.
Main Methods:
- Review of reported cases and clinical data on Trastuzumab-induced cardiotoxicity.
- Monitoring of cardiac function using physical examination and left ventricular ejection fraction measurements.
Main Results:
- Cardiotoxicity risk is 4% with monotherapy and 27% with combination therapy (anthracycline and cyclophosphamide).
- Severe outcomes like death or disability are uncommon; most effects are mild to moderate and manageable.
- Cardiac symptoms resemble anthracycline-induced cardiomyopathy but Trastuzumab toxicity typically responds to treatment or drug cessation.
Conclusions:
- Trastuzumab-associated cardiotoxicity is generally manageable and often reversible.
- Early detection and regular monitoring of cardiac function are crucial for patients receiving Trastuzumab.
- Many patients can continue Trastuzumab therapy after cardiac events with appropriate management.